WebOct 5, 2024 · Gemini will concentrate its resources to advance GEM103 for the treatment of genetically defined age-related macular degeneration (AMD). GEM103 has the potential to be a best-in-class complement regulator for the treatment of GA,” said Jason Meyenburg, Chief Executive Officer of Gemini Therapeutics, Inc. WebNov 13, 2024 · CAMBRIDGE, Mass. & SAN FRANCISCO--(BUSINESS WIRE)-- Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that the Phase 1 study of GEM103, the Company’s investigational treatment …
Gemini Therapeutics Announces Poster Presentation at AAO 2024
WebMar 1, 2024 · Gemini Therapeutics, a clinical-stage biopharma company dedicated to developing treatments for genetically defined age-related macular degeneration (AMD), … WebDec 29, 2024 · Disc Medicine Announces Completion of Merger with Gemini Therapeutics. The combined company will operate as Disc Medicine and will trade on the Nasdaq … raytheon mx-1
Axsome Therapeutics Announces Publication of Pivotal GEMINI …
WebNov 23, 2024 · Find the latest press releases from Gemini Therapeutics, Inc. Common Stock (GMTX) at Nasdaq.com. WebMar 1, 2024 · Gemini Therapeutics, a clinical-stage biopharma company dedicated to developing treatments for genetically defined age-related macular degeneration (AMD), announced a series of corporate updates Monday. Among these is a corporate restructuring that will see a drastic 80% of the company's workforce laid off. ... In the press release, … WebCompleted reverse merger with Gemini Therapeutics, debuting on Nasdaq as “IRON” and ending 2024 with approximately $194.6 million in cash and cash… read more Disc Medicine Announces Collaboration with National Institutes of Health for Phase 2 Clinical Study of Bitopertin in Patients with Diamond-Blackfan Anemia (DBA) simply kitchens usa